Clinical Trial Update: Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing orelabrutinib plus rituximab versus lenalidomide plus rituximab in relapsed/refractory marginal zone lymphoma is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Relapsed/Refractory Marginal Zone Lymphoma | Phase 3 | Status: RECRUITING